A plain-language, continually updated guide from Dr. Matt Chalmers’ clinical reference on hormones and peptides.
Retatrutide is a triple agonist — it activates the GLP-1, GIP, and glucagon receptors all at once, adding a third pathway on top of what Semaglutide and Tirzepatide already do. That glucagon piece is what genuinely sets it apart: it’s the first compound in this drug class shown to meaningfully raise your resting metabolic rate, not just reduce how much you eat. Our reference material frames it simply — GLP-1 asks “have we eaten enough?”, GIP asks “where should nutrients go?”, and glucagon asks “how do we burn more energy?” Retatrutide answers all three at once.
In its Phase 2 trial (published in the New England Journal of Medicine, 2023), it produced an average 24.2% weight loss at 48 weeks. Interim Phase 3 TRIUMPH trial data has shown 28.7% at the 12 mg dose and 26.4% at 9 mg, with 9 mg emerging as the preferred balance of results and tolerability. An FDA filing is expected sometime in late 2026 or 2027.
“As of July 2026 this is by far my favorite peptide. The metabolic change this is allowing will change the world. I am watching diabetes, dementia, PCOS, endometriosis, fatty liver, sleep apnea and lots of other things tied to insulin resistance, just melt away. It is important that you maintain the environment for this though.”
— Dr. Matt Chalmers, The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health
Retatrutide’s glucagon-driven fat-burning is significant enough that our reference material treats its nutrient needs as the highest priority in this entire drug class. Acetyl-L-carnitine is considered the single most critical addition, since glucagon mobilizes large volumes of fatty acids that require carnitine to actually enter the mitochondria for burning. Protein needs are also elevated (1.6–2.0 g per kg of body weight, with resistance training, is the recommended minimum), since the glucagon receptor raises the risk of muscle breakdown alongside fat loss. B vitamins, CoQ10, alpha-lipoic acid, and magnesium all matter more here too, given the increased metabolic throughput.
Retatrutide remains in Phase 3 clinical trials and is not FDA-approved for any indication. An FDA filing is anticipated in late 2026 or 2027 based on current trial timelines. It is not currently available for prescribing or compounding outside of a clinical trial. This page is provided for educational purposes only, in anticipation of possible future approval, and is not an offer to provide Retatrutide at this time.
Retatrutide is investigational and not yet FDA-approved, so there is no approved indication to cite. In the Phase 2 and Phase 3 trials conducted so far, researchers have reported substantial average weight reduction compared to dual-agonist therapies, attributed to the added glucagon-receptor activation increasing energy expenditure and shifting fuel use toward stored fat. These are trial-reported findings, not an approved claim, and Retatrutide is not currently available for prescribing outside of a clinical trial.
Glucagon receptor activation is documented in physiology to increase resting energy expenditure and promote lipolysis, independent of dietary changes. It’s also the first mechanism in this drug class shown to meaningfully activate the body’s mitochondrial biogenesis pathway. Combining this with GLP-1/GIP activity is the proposed mechanism behind Retatrutide’s trial results, which is why it’s a closely watched compound in metabolic research.
Learn more about the receptor that sets Retatrutide apart: Glucagon. Compare with Semaglutide and Tirzepatide.
Learn about our Metabolic Reset program, which addresses insulin resistance, sleep, and hormones together.
This page draws on The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health by Dr. Matt Chalmers — Pillars of Wellness’ clinical reference on hormone and peptide therapy.
